Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab

We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Flores-Gonzalez, Ramon E, Hernandez, Jeffrey, Tornes, Leticia, Rammohan, Kottil, Delgado, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816891/
https://www.ncbi.nlm.nih.gov/pubmed/33508573
http://dx.doi.org/10.1016/j.msard.2021.102777
_version_ 1783638529036779520
author Flores-Gonzalez, Ramon E
Hernandez, Jeffrey
Tornes, Leticia
Rammohan, Kottil
Delgado, Silvia
author_facet Flores-Gonzalez, Ramon E
Hernandez, Jeffrey
Tornes, Leticia
Rammohan, Kottil
Delgado, Silvia
author_sort Flores-Gonzalez, Ramon E
collection PubMed
description We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.
format Online
Article
Text
id pubmed-7816891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78168912021-01-21 Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab Flores-Gonzalez, Ramon E Hernandez, Jeffrey Tornes, Leticia Rammohan, Kottil Delgado, Silvia Mult Scler Relat Disord Correspondence We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines. Elsevier B.V. 2021-04 2021-01-19 /pmc/articles/PMC7816891/ /pubmed/33508573 http://dx.doi.org/10.1016/j.msard.2021.102777 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Flores-Gonzalez, Ramon E
Hernandez, Jeffrey
Tornes, Leticia
Rammohan, Kottil
Delgado, Silvia
Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title_full Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title_fullStr Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title_full_unstemmed Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title_short Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab
title_sort development of sars-cov-2 igm and igg antibodies in a relapsing multiple sclerosis patient on ofatumumab
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816891/
https://www.ncbi.nlm.nih.gov/pubmed/33508573
http://dx.doi.org/10.1016/j.msard.2021.102777
work_keys_str_mv AT floresgonzalezramone developmentofsarscov2igmandiggantibodiesinarelapsingmultiplesclerosispatientonofatumumab
AT hernandezjeffrey developmentofsarscov2igmandiggantibodiesinarelapsingmultiplesclerosispatientonofatumumab
AT tornesleticia developmentofsarscov2igmandiggantibodiesinarelapsingmultiplesclerosispatientonofatumumab
AT rammohankottil developmentofsarscov2igmandiggantibodiesinarelapsingmultiplesclerosispatientonofatumumab
AT delgadosilvia developmentofsarscov2igmandiggantibodiesinarelapsingmultiplesclerosispatientonofatumumab

Ejemplares similares